“Pegfilgrastim Biosimilar Insight, 2020,” report by DelveInsight provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in Pegfilgrastim Biosimilars landscape.
It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pegfilgrastim Biosimilar therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pegfilgrastim Biosimilars Marketed Drugs
Delveinsight provides detailed information on the Pegfilgrastim Biosimilars marketed drugs. Some of the key drugs covered in the report include:
Nyvepria: Pfizer - Nyvepria is a biosimilar to Neulasta, is approved by the FDA to help reduce the chance of infection due to a low white blood cell count in people with non-myeloid cancer who receive anti-cancer medicines, like chemotherapy, that can cause fever and low white blood cell count. This condition, known as febrile neutropenia, is a common side effect of many types of chemotherapy and lowers the body’s ability to defend itself against infections.
Further product details are provided in the report, visit to get free sample page at: Pegfilgrastim Biosimilars Products
Pegfilgrastim Biosimilars Emerging Drugs
Delveinsight provides detailed information on the Pegfilgrastim Biosimilars Emerging Drugs. Some of the key emerging drugs drugs covered in the report include:
PF-06881894: Pfizer - PF-06881894 is a potential biosimilar to Neulasta (Pegfilgrastim) which was initially being developed by Hospira pharma and is currently being developed by Pfizer. The drug is currently in the registration phase of development for the treatment of Neutropenia.
Further product details are provided in the report, visit to get free sample page at: Pegfilgrastim Biosimilars Products
Pegfilgrastim Pipeline Development Activities
- The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stages. It also analyses Pegfilgrastim biosimilars drugs key players involved in developing key drugs.
- The report also covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pegfilgrastim biosimilar drugs.
Pegfilgrastim Biosimilar Report Assessment
- Marketed Product profiles
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Sales Assessment
- Inactive drugs assessment
- Unmet Needs
Some of the key Pegfilgrastim Biosimilars Companies include:
Merck & Co, Zydus Cadila, Virchow Group, USV, Sandoz, Reliance Life Sciences, Ratiopharm, PharmaEssentia, Pfizer, Pfenex, Nanogen Biopharmaceutical, Mylan, Mundipharma Biologics, Lupin, Jiangsu Hengrui Medicine Co, Intas Biopharmaceuticals, Hospira, CinnaGen, Cinfa Biotech, Chong Kun Dang, Biocure Technology, Biocon, Apotex, Accord Healthcare, and many others.
Some of the key Pegfilgrastim Biosimilars Products covered in the report include:
MK-6302, Peg G-CSF, PEG Neutrogen, Dulastin, Udenyca, PegaGen, B12019/Pelmeg, CKD-12101, Neutropeg (Apo-Peg), Pelgraz, and many others.
For more details, visit: Pegfilgrastim Biosimilars Marketed and Emerging Drugs Analysis